For example, there is considerable interest in combining venetoclax with FLT3 inhibitors to improve outcomes in AML, and these drugs may impair the function of OATP1B1 and cause unanticipated DDIs that can remain unnoticed, compromising the safety of such combinatorial modalities. Here, SLCO1B1 is linked to acute myeloid leukemia.